Please login to the form below

Not currently logged in

FDA warns web fraudsters over H1N1 claims

The US FDA has issued warning letters to more than 50 websites marketing products that claim to diagnose, prevent, treat or cure swine (H1N1) flu

The US Food and Drug Administration (FDA) has issued warning letters to more than 50 websites marketing products that claim to diagnose, prevent, treat or cure swine (H1N1) flu.

Teams from the FDA identified websites promoting and marketing products that had not been approved, authorised or cleared by the official body and pose a potential threat to public health. These included a shampoo that claimed to protect against the H1N1 virus, a spray claiming to leave a layer of virus-killing ionic silver on one's hands, and a 'new' supplement claiming to cure infection with the H1N1 virus in four to eight hours.

Over 50 letters have been issued by the agency warning the operators of such websites that they must not market products claiming to diagnose, mitigate, prevent, treat, or cure the 2009 H1N1 flu virus that are not approved, cleared, or authorised by the FDA. Over 66 per cent of the websites warned have now removed the offending products and/or claims. Details of offending websites were also posted on the FDA's website.

"We are committed to aggressively pursuing those who attempt to take advantage of a public health emergency by promoting and marketing unapproved, uncleared, or unauthorised products," said Dr Margaret A Hamburg, commissioner of food and drugs.

The warning letters were issued by email and requested a response within 48 hours. Failure by offending websites to act on the warnings may result in further civil or criminal enforcement action, including criminal prosecution, seizure and injunction. 


17th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...